Trimethoprim-sulfamethoxazole tablets

This product is a compound preparation of sulfamethoxazole (SMZ), sulfadiazine (SD) and trimethoprim (TMP). It has a broad antibacterial spectrum, strong antibacterial effect, and synergistic antibacterial or bactericidal effect. It has good antibacterial activity against most Gram-positive and negative bacteria, including non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Pneumococcus, Escherichia coli, Klebsiella, Salmonella, Proteus, Morganella, Shigella and other Enterobacteriaceae, gonococci, meningococci, Haemophilus influenzae, etc. In recent years, bacterial resistance to this product is common, especially Shigella and other Enterobacteriaceae bacteria, so it is rarely used clinically. In addition, it also has good antibacterial activity against Vibrio cholerae, Chlamydia trachomatis, etc. in vitro. Its mechanism of action is that both SMZ and SD can compete with p-aminobenzoic acid for dihydrofolate synthase, making it impossible for bacteria to synthesize dihydrofolate, while TMP inhibits the dihydrofolate reductase of bacteria, hindering the reduction of dihydrofolate to tetrahydrofolate. When the three are used together, they have a double blocking effect on the bacterial synthesis of tetrahydrofolate, so their antibacterial effect is stronger than that of a single drug, and the strains resistant to them are also reduced accordingly.

This product is a compound preparation, each tablet contains sulfamethoxazole, sulfadiazine and trimethoprim

This product is white tablets.

It is mainly used for urinary tract infections, intestinal infections, acute attacks of chronic bronchitis in adults, acute otitis media, etc. caused by bacteria sensitive to this product.

The usual oral dose for adults is: 2 tablets at a time, twice a day, and the first dose is doubled. The course of treatment for acute exacerbation of chronic bronchitis is at least 10 to 14 days; the course of treatment for urinary tract infection is 7 to 10 days; the course of treatment for bacillary dysentery is 5 to 7 days; the course of treatment for acute otitis media is 10 days

1. Allergic reactions are relatively common. It can manifest as drug rash. In severe cases, exudative erythema multiforme, exfoliative dermatitis and bullous epidermolysis atrophic dermatitis may occur; there are also serum sickness-like reactions such as photosensitivity reaction, drug fever, joint and muscle pain, fever, etc. Anaphylactic shock is occasionally seen. 2. Neutropenia or deficiency, thrombocytopenia, and occasionally aplastic anemia. Patients may show symptoms of sore throat, fever and bleeding tendency. 3. Hemolytic anemia and hemoglobinuria. This is prone to occur in patients who lack glucose-6-phosphate dehydrogenase after using sulfonamides, and is more common in newborns and children than in adults. 4. Hyperbilirubinemia and neonatal kernicterus. Because this product competes with bilirubin for protein binding sites, it can cause an increase in free bilirubin. Newborns have imperfect liver function,

1. Patients who are allergic to sulfonamides are contraindicated. 2. Since this product blocks the metabolism of folic acid and aggravates the folate deficiency in patients with megaloblastic anemia, patients with this disease are contraindicated to use this product. 3. Pregnant and lactating women are contraindicated to use this product. 4. Infants under 2 months old are contraindicated to use this product. 5. Patients with liver and kidney damage are contraindicated to use this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. The combined use of urine alkalinizing drugs can increase the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with para-aminobenzoic acid. Para-aminobenzoic acid can replace this product and be taken up by bacteria, and the two are antagonistic to each other. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action time or toxic reactions. Therefore, when these drugs are used at the same time as this product, or when used after the application of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. The combined use with bone marrow suppressive drugs may enhance the adverse reactions of such drugs on the hematopoietic system. Such as leukopenia, thrombocytopenia, etc. If there is an indication to use the two drugs together, the possible toxic reactions should be closely observed.

Sealed and stored in a cool place.

Sulfadiazine 0.2 g, sulfadiazine 0.2 g, trimethoprim 80 mg

36 months